B38-CAP is structured as a carboxypeptidase and derived from Paenibacillus sp. The molecule, an Angiotensin Converting Enzyme 2 (ACE2)-like enzyme, shares structural similarities to the mammalian ACE2. B38-CAP is an... B38-CAP is an ACE2-like enzyme which decreases angiotensin II levels.
- Mechanism
- Curator reviewed
Angiotensin Converting Enzyme 2 (ACE2) is a recently discovered enzyme that degrades Angiotensin II (known as Ang 1-8) into Ang1-7. Angiotensin II exerts actions like inflammation, ROS production, and vasoconstriction, and is implicated in acute respiratory distress syndrome (ARDS). Its conversion to Ang1-7 by ACE2 contrasts these actions as Ang1-7 promotes vasodilation, anti-inflammation, and NO release, attenuating tissue injury, including ARDS-associated injury. Additional administration of ACE2 by way of a recombinant protein is thought to aid in conversion of excessive Ang1-8 associated with ARDS into Ang1-7, and help reduce the depelatory effects of the renin-angiotensin system. This compound, as such, is being investigated for lung injury and ARDS associated with COVID-19.
- Also known as
- B38-CAP · rbACE2
- Code names
- Recombinant Bacterial ACE2 Receptors-like Enzyme
Resolves to
What you can answer from here — as of July 08, 2026
Which drugs share a target with Recombinant Bacterial ACE2 Receptors-like Enzyme, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account